{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-287073","form_type":"8-K","ticker":"GRTX","cik":"0001563577","company_name":"Galera Therapeutics, Inc.","filed_at":"2024-12-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.797453+00:00","generated_at":"2026-05-28T21:47:24.473372+00:00","sec_items":["1.01","5.03","2.01","3.02","3.03","5.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Galera Therapeutics acquires Nova Pharmaceuticals in merger; issues Series B Preferred and closes $2.885M PIPE","bullets":["Acquisition closed Dec 30; Galera issued 119,318 shares of Series B Non-Voting Convertible Preferred (1,000-to-1 conversion).","Raised $2.885M via private placement of 44,111,260 common shares and pre-funded warrants.","Three directors resigned (Powell, West, Cunningham); Nancy Chang and Michael Friedman appointed as Class I directors.","Board reduced from six to five; stockholders to vote on Series B conversion and reverse split within 12-18 months.","90-day lock-up on shares from merger for certain securityholders and directors/officers."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-287073","json":"https://secwatch.observer/filing/0001193125-24-287073.json","markdown":"https://secwatch.observer/filing/0001193125-24-287073.md","text":"https://secwatch.observer/filing/0001193125-24-287073.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563577/000119312524287073/0001193125-24-287073-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563577/000119312524287073/d899535d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T21:47:24.473372+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b02f3f26b15e0fedfd139eb2f22aa21c439cc288","claim":"Galera Therapeutics, Inc.: Galera intends to file a Certificate of Elimination to eliminate the Series A Junior Participating Preferred Stock designation, returning those shares to authorized but unissued preferred stock (effective 2024-12-31).","evidence_excerpt":"Galera intends to file a Certificate of Elimination eliminating from its Certificate of Incorporation, as amended, the designation of certain shares of its preferred stock as Series A Junior Participating Preferred Stock, which had been designated for potential use in connection with the Rights Agreement.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1563577/000119312524287073/0001193125-24-287073-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-12-31"}],"fact_type":"governance_change"},{"claim_id":"a93ecab9b1da995be02ada3fe39a58119d671f0b","claim":"Galera Therapeutics, Inc. completed an acquisition involving Nova Pharmaceuticals, Inc. for 119,318.285 shares of preferred stock, par value $0.001 per share, designated as Series B Non-Voting Convertible Preferred Stock (closed 2024-12-30).","evidence_excerpt":"(17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per share GRTX OTC Pink Market Series A Junior Participating Preferred Stock (Purchase Rights) N/A OTC Pink Market Indicate by check mark whether the registrant is an","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1563577/000119312524287073/0001193125-24-287073-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Nova Pharmaceuticals, Inc."},{"label":"Consideration","value":"119,318.285 shares of preferred stock, par value $0.001 per share, designated as Series B Non-Voting Convertible Preferred Stock"},{"label":"Closing","value":"2024-12-30"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}